Primary Hyperoxaluria Mutation Genotyping
Correlation of Disease Expression With Specific Genetic Mutations in Primary Hyperoxaluria
Sponsor: Mayo Clinic
A observational or N/A phase clinical study on Primary Hyperoxaluria, this trial is completed. The trial is conducted by Mayo Clinic and has accumulated 10 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: PHASE1 → None
-
Aug 2017 — Apr 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Aug 2017 [monthly]
Completed PHASE1
First recorded
Dec 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Oxalosis and Hyperoxaluria Foundation (OHF)
For direct contact, visit the study record on ClinicalTrials.gov .